Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 Lot-to-Lot Consistency Study (PNEU-TRUE)
NCT03950856Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Apr 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 6
01
Overview
A Phase 3 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal disease, sponsored by Merck & Co.. Started Jun 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT03950856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950856.